Urinary incontinence has three main subtypes including stress, urge and mixed, and is estimated to affect 100 million women in the seven major markets. Drug therapy for urinary incontinence has focused on overactive bladder, worth over $1.3 billion in 2003. Lilly/BI's Yentreve, launched in 2004, is the first drug treatment for stress incontinence, the most prevalent subtype of the condition.
Scope
In-depth primary research interviews with key opinion leaders from the US and Europe to add insight on market developments and unmet needs
Analysis of recent market events including new drug launches and impact on the market
Secondary resources include IMS MIDAS sales and promotional data across the seven major markets, IDdb, IMS R&D Focus, Medline
Report Highlights Despite the high prevalence of urinary incontinence among women, few are diagnosed and treated due to a number of barriers preventing help-seeking behavior. There is a need to greater disease education among patients to lessen embarrassment about the condition and raise awareness of effective treatments.
The UI market was worth $1.3 billion in 2003 with sales dominated by leading overactive bladder drugs including Detrol (Pfizer) and oxybutynin in its various forms. New drug launches in OAB Vesicare (Yamanouchi) and Enablex (Novartis) could usurp Pfizer's dominance, while Yentreve will open up a new and underserved segment and driving growth.
Opinion leaders have identified a number of unmet needs in the urinary incontinence market, particularly the need for greater support for health professionals in terms of differentiating, diagnosing and treating UI subtypes in the long term and the need for greater disease awareness both among patients and physicians.
Reasons to Purchase
Understand barriers to treatment in the female UI population including obstacles in help-seeking behavior and difficulties in the diagnostic pathway
Identify physicians key concerns in urinary incontinence including unmet needs and desirable attributes of novel drugs for Overactive Bladder
Evaluate new drugs entering the market including key efficacy and safety trial data and their potential impact on the market
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
